It's more about my interactions with RAC over the past 24 months. During the AML trial, I referred at least three potential patients to RAC, but since they were overseas, they couldn't participate. I've also referred at least two oncological practices to RAC. Whether any communication followed from those referrals, I'm not sure. So, for me, it's more about tying up loose ends on my side. I'm not prioritizing one path over another. Although it's unlikely, just imagine how I would be boasting if the investigator I referred ended up being involved!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
-0.040(3.23%) |
Mkt cap ! $208.4M | |||
| Open | High | Low | Value | Volume |
| $1.24 | $1.24 | $1.20 | $103.7K | 85.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12091 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 9720 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |